US4275064A
(en)
*
|
1976-02-06 |
1981-06-23 |
Interx Research Corporation |
Transient pro-drug forms of xanthine derivatives and their use as topical anti-inflammatory agents
|
US4133893A
(en)
*
|
1977-05-26 |
1979-01-09 |
Calbiochem Behring Corp. |
Topical treatment of skin diseases
|
SE416810C
(sv)
*
|
1977-10-14 |
1982-05-11 |
Draco Ab |
Forfarande for framstellning av xantinderivat med antiallergisk aktivitet
|
DE2922159A1
(de)
*
|
1979-05-31 |
1980-12-04 |
Boehringer Mannheim Gmbh |
Neue xanthin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
|
DK172081A
(da)
*
|
1980-04-21 |
1981-10-22 |
Merck & Co Inc |
Mercaptoforbindelse og fremgangsmaade til fremstilling deraf
|
US4341783A
(en)
*
|
1980-07-31 |
1982-07-27 |
Lemmon Company |
Topical use of dyphylline and dyphylline containing compositions
|
GB8501488D0
(en)
*
|
1985-01-21 |
1985-02-20 |
Beecham Group Plc |
Treatment
|
IT1184139B
(it)
*
|
1985-01-23 |
1987-10-22 |
Proter Spa |
Composti ad attivita' mucolitica e broncodilatatrice,procedimento per la loro preparazione e composizioni farmaceutiche che licontengono come principi attivi
|
US4923872A
(en)
*
|
1986-08-26 |
1990-05-08 |
Warner-Lambert Co. |
Analogues of pyrrolo[3,2d]pyrimidin-4-ones
|
US4988702A
(en)
*
|
1986-08-26 |
1991-01-29 |
Warner-Lambert Company |
Novel 9-deazaguanines
|
US4921858A
(en)
*
|
1986-10-24 |
1990-05-01 |
Warner-Lambert Company |
7-deazaguanines as immunomodulators
|
US5321029A
(en)
*
|
1988-11-14 |
1994-06-14 |
Beecham-Wuelfing Gmbh & Co.K.G. |
Xanthines
|
GB8826595D0
(en)
*
|
1988-11-14 |
1988-12-21 |
Beecham Wuelfing Gmbh & Co Kg |
Active compounds
|
US5886162A
(en)
*
|
1989-11-03 |
1999-03-23 |
Research Foundation Of State University Of New York |
Lipophilic diakylaminomethylene prodrug derivatives for the inhibition of replication of viruses
|
US5726311A
(en)
*
|
1989-11-29 |
1998-03-10 |
Biocryst Pharmaceuticals, Inc. |
7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo 3,2-d!pyrimidine and pharmaceutical uses and compositions containing the same
|
DE4019892A1
(de)
*
|
1990-06-22 |
1992-01-02 |
Boehringer Ingelheim Kg |
Neue xanthinderivate
|
JPH05294966A
(ja)
*
|
1992-02-17 |
1993-11-09 |
Kyowa Hakko Kogyo Co Ltd |
キサンチン誘導体
|
US5340813A
(en)
*
|
1992-11-09 |
1994-08-23 |
Cell Therapeutics, Inc. |
Substituted aminoalkyl xanthine compounds
|
US5817662A
(en)
*
|
1992-11-09 |
1998-10-06 |
Cell Therapeutics, Inc. |
Substituted amino alkyl compounds
|
US6103730A
(en)
*
|
1994-03-24 |
2000-08-15 |
Cell Therapeutics, Inc. |
Amine substituted compounds
|
US5807861A
(en)
*
|
1994-03-24 |
1998-09-15 |
Cell Therapeutics, Inc. |
Amine substituted xanthinyl compounds
|
US5801182A
(en)
*
|
1994-03-24 |
1998-09-01 |
Cell Therapeutics, Inc. |
Amine substituted compounds
|
DE19535504A1
(de)
*
|
1995-09-25 |
1997-03-27 |
Bayer Ag |
Substituierte Xanthine
|
US6541517B1
(en)
|
1999-09-03 |
2003-04-01 |
Donald M. Murphy |
Treatment of skin disorders
|
US6117904A
(en)
*
|
1999-09-03 |
2000-09-12 |
Murphy; Donald M. |
Treatment of pruritus
|
KR100926247B1
(ko)
*
|
2001-02-24 |
2009-11-12 |
베링거 잉겔하임 파르마 게엠베하 운트 코 카게 |
크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법
|
RU2196583C1
(ru)
*
|
2001-05-29 |
2003-01-20 |
Барбинов Вячеслав Викторович |
Средство для наружной терапии псориаза и способ его изготовления
|
CN107674077A
(zh)
*
|
2002-08-21 |
2018-02-09 |
勃林格殷格翰制药两合公司 |
8‑[3‑氨基‑哌啶‑1‑基]‑黄嘌呤化合物,其制备方法及作为药物制剂的用途
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
US7501426B2
(en)
*
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
EP1852108A1
(de)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Zusammensetzungen von DPP-IV-Inhibitoren
|
NZ573360A
(en)
|
2006-05-04 |
2012-08-31 |
Boehringer Ingelheim Int |
Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
|
EP2190434B1
(de)
*
|
2007-08-17 |
2019-04-17 |
Boehringer Ingelheim International GmbH |
Purin-derivate zur verwendung in der behandlung von erkrankungen im zusammenhang mit fap
|
AR071175A1
(es)
|
2008-04-03 |
2010-06-02 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
JP5906086B2
(ja)
*
|
2008-08-15 |
2016-04-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Fab関連疾患の治療に用いるためのプリン誘導体
|
JP2012502081A
(ja)
|
2008-09-10 |
2012-01-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糖尿病及び関連症状の治療のための組み合わせ治療
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
TWI508965B
(zh)
|
2008-12-23 |
2015-11-21 |
Boehringer Ingelheim Int |
有機化合物的鹽形式
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
JP2013512229A
(ja)
|
2009-11-27 |
2013-04-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
遺伝子型が同定された糖尿病患者のリナグリプチン等のddp−iv阻害薬による治療
|
NZ602921A
(en)
|
2010-05-05 |
2016-01-29 |
Boehringer Ingelheim Int |
Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
|
MX2012014247A
(es)
|
2010-06-24 |
2013-01-18 |
Boehringer Ingelheim Int |
Terapia para la diabetes.
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
EP3517539B1
(de)
|
2011-07-15 |
2022-12-14 |
Boehringer Ingelheim International GmbH |
Substituiertes dimeres chinazolinderivat, dessen herstellung und dessen verwendung in pharmazeutischen zusammensetzungen zur behandlung von diabetes typ i und ii
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
WO2013171167A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
US9526728B2
(en)
|
2014-02-28 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Medical use of a DPP-4 inhibitor
|
EP3468562A1
(de)
|
2016-06-10 |
2019-04-17 |
Boehringer Ingelheim International GmbH |
Kombinationen aus linagliptin und metformin
|